Design and development of adjuvant-active nonionic block copolymers

Journal of Pharmaceutical Sciences

Volumn 87, Issue 11, 1998, Pages 1357-1362

  Newman, Mark J ^a  

^a Vaxcel Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COPOLYMER; ETHYLENE OXIDE; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; OVALBUMIN; POLOXAMER; PROPYLENE OXIDE; SURFACTANT; TRIPLE VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; CONFERENCE PAPER; CONTROLLED STUDY; DRUG DESIGN; DRUG FORMULATION; DRUG SYNTHESIS; HELPER CELL; IMMUNE RESPONSE; MOLECULAR WEIGHT; MOUSE; NONHUMAN; T LYMPHOCYTE; VACCINE PRODUCTION;

EID: 0031765180     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1021/js980072c     Document Type: Conference Paper

References (55)

1. Mosrnann, T. R.; Coffinan, R. L. TH1 and TH2 cells: Different patterns of lymphokine secretion lead to different functional properties. Annu. Rev, Immunol. 1989, 7, 145-173.
2. Paul, W. E.; Seder, R. A. Lymphocyte responses and cytokines. Cell 1994, 76, 241-251.
3. Feghali, C. A.; Wright, T. M. Cytokines in acute and chronic inflammation. Frontiers BioSci. 1997, 2, 12-26.
4. Audibert, F.; Chedid, L.; Lefrancier, P.; Choay, J. Distinctive adjuvanticity of synthetic analogues of mycobacterial watersoluble components. Cell. Immunol. 1976, 21, 243-250.
5. Damais, C.; Parant, M.; Chedid, L.; Lefrancier, P.; Choay, J. In vitro spleen cell responsiveness to various analogues of MDP (Af-acetylmuramyl-L-isoglutamine), a synthetic immunoadjuvant, in MDP high-responder mice. Cell. Immunol. 1978,35, 173-181.
6. Tanaka, A.; Nagao, S.; Nagao, R.; Kotani, S.; Shiba, T.; Kusumoto, S. Stimulation of the reticuloendothelial system of mice by muramyl dipeptide. Infect. Immun. 1976,24, 302310.
7. Gery, L; Kruger, J.; Spiesei, S. Z. Stimulation of B-lymphocytes by endotoxin. Reactions of thymus-deprived mice and karyotypic analysis of dividing cell in mice bearing T6T6 thymus grafts. J. Immunol. 1972, 108, 1088-1094.
8. Johnson, A. G.; Tomai, M. A. A study of the cellular and molecular mediators of the adjuvant action of a nontoxic monophosphoryl lipid A. Adv. Exp. Med. Biol. 1990, 256, 567-579.
9. Tomai, M. A.; Johnson, A. G. T cell and interferon-gamma involvement in the adjuvant action of detoxified endotoxin. J. Biol. Response Modif. 1989, 8, 625-635.
10. Arend, W. P.; Massoni, R. J. Characteristics of bacterial lipopolysaccharide induction of interleukin 1 synthesis and secretion by human monocytes. Clin. Exp. Immunol. 1986, 64, 656-664.
11. Flebbe, L. M.; Braley-Mullen, H. Immunppotentiating effects of the adjuvants SGP and Quil A. I. Antibody responses to T dependent and T independent antigens. Cell. Immunol. 1986, 99, 119-127.
12. Flebbe,'L. M.; Braley-Mullen, H. Immunopotentiation by SGP and Quil A. II. Identification of responding cell populations. Cell. Immunol. 1986, 99, 128-139.
13. Kensil, C. R.; Patel, U.; Lennick, M.; Marciani, D. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria molina cortex. J. Immunol. 1991, 146, 431-437.
14. Wu, J.-Y.; Gardner, B. H.; Kushner, N. N.; Pozzi, L.-A. M.; Kensil, C. R.; Cloutier, P. A.; Coughlin, R. T.; Newman, M. J. Accessory cell requirements for saponin adjuvant-induced class IMHC antigen-restricted cytotoxic T-lymphocytes. Cell. Immunol. 1994, 154, 393-406.
15. Gupta, R. K.; Rost, B. E.; Relyveld, E.; Siber, G. R. Adjuvant properties of aluminum and calcium compounds. In Vaccine Design: The Subunit and Adjuvant Approach, Powell, M. F., Newman, M. J., Eds.; Plenum Press: New York 1995; pp 229-248.
16. Ott, G.; Barchfeld, G. L.; Chernoff, D.; Radhakrishnan, R.; van Hoogevest, P.; Van Nest, G. MF59: Design and evaluation of a safe and potent adjuvant for human vaccines. In Vaccine Design: The Subunit and Adjuvant Approach, Powell, M. F., Newman, M. J., Eds.; Plenum Press: New York, 1995; pp 277-296.
17. McKercher, P. D. Oil adjuvants: Their use in veterinary biologies. In Advances in Carriers and Adjuvants of Veterinary Biologies, Nervig, R. M., Gough, P. M., Kaeberle, M. L., Whetstone, C. A., Eds.; Iowa State University Press: Ames, 1986; pp 115-135.
18. Woodard, L. F.; Jasman, R. L. Stable oil-in-water emulsions: preparation and use as vaccine vehicles for lipophilic adjuvants. Vaccine 1985, 3, 137-142.
19. Hilleman, M. R. Critical appraisal of emulsified oil adjuvants applied to viral vaccines. Prog. Med. Virol. 1966, 8, 131 151.
20. Allison, A. C.; Gregoriadis, G. Liposomes as immunological adjuvants. Nature 1974, 252, 252-255.
21. Gregoriadis, G.; Davis, D.; Davies, A. Liposomes as immunological adjuvants: antigen incorporation studies. Vaccine 1987, 5, 145-151.
22. Gluck, R. Liposomal presentation of antigens for human vaccines. In Vaccine Design: The Subunit and Adjuvant Approach, Powell, M. F., Newman, M. J., Eds.; Plenum Press: New York, 1995; pp 325-345.
23. Cleland, J. L. Design and production of single-immunization vaccines using polylactide polyglycolide microsphere systems. In Vaccine Design: The Subunit and Adjuvant Approach, Powell, M. F.; Newman, M. J., Eds.; Plenum Press: New York, 1995; pp 439-462.
24. Eldridge, J. H.; Staas, J. K.; Meulbroek, J. A.; McGhee, J. R.; Tice, T. R.; Giller, R. M. Biodegradable microspheres as a vaccine delivery. Mol. Immunol. 1993, 28, 287-294.
25. Alving, C. R. Liposomal vaccines: Clinical status and immunological presentation for humoral and cellular immunity. Ann. N.Y. Acad. Sei. 1995, 754, 143-152.
26. Raychaudhuri, S.; Tonks, M.; Carbone, F.; Ryskamp, T.; Morrow, W. J. W.; Hanna, N. Induction of antigen-specific class I-restricted cytotoxic T cells by soluble proteins in vivo. Proc. Natl. Acad. Sei. 1992, 89, 8308-8312.
27. Fenton, R. G.; Taub, D. D.; Kwak, L. W.; Smith, M. R.; Longo, D. L. Cytotoxic T-cell response and in vivo protection against tumor cells harboring activated ras proto-oncogenes. J. Natl. Cancer Inst. 1993, 85, 1294-1302.
28. Moore, A.; McGuirk, P.; Adams, S.; Jones, W. C.; McGee, J. P.; O'Hagan, D. T.; Mills, K. H. G. Immunization with a soluble recombinant HIV protein entrapped in biodegradable microparticles induces HIV-specific CD8+ cytotoxic T lymphocytes and CD4+ Thl cells. Vaccine 1995,13, 1741-1749.
29. Hunter, R. L.; Olsen, M. R.; Bennett, B. Copolymer adjuvants and Titermax. In The Theory and Practicle Application of Adjuvants, Stewart-Tull, D. E. S., Ed.; John Wiley & Sons: New York, 1995; pp 51-94.
30. Hunter, R. L.; Strickland, F.; Kezdy, F. Studies on the adjuvant activity of nonionic block polymer surfactants. I. The role of hydrophile-lipophile balance. J. Immunol. 1981, 127, 1244-1250.
31. Hunter, R. L.; Bennett, B. The adjuvant activity of nonionic block polymer surfactants. III. Characterization of selected biologically active surfaces. Scand. J. Immunol. 1986, 23, 287-300.
32. Howerton, D. A.; Hunter, R. L.; Ziegler, H. K.; Check, I. J. The induction of macrophage la expression in vivo by synthetic copolymer L81. J. Immunol. 1990,144,1578-1584.
33. Hunter, R. L.; Bennett, B. The adjuvant activity of nonionic block polymer surfactants. II. Antibody formation and inflammation related to the structure of triblocks and octablock copolymers. J. Immunol. 1984, 133, 3167-3175.
34. Hilleman, M. R.; Woohour, A.; Friedman, A.; Weibel, R. E.; Stokes, J. The clinical application of adjuvant 65. Ann. Allergy 1972, 30, 152-158.
35. Keitel, W.; Couch, R.; Bond, N.; Adair, S.; Van Nest, G.; Dekker, C. Pilot evaluation of influenza virus vaccine (IW) combined with adjuvant. Vaccine 1993, 11, 909-913.
36. Lundsted, L. G.; Schmolka, I. R. The synthesis and properties of block copolymer surfactants. In Block and Graft Copolymerization; Ceresa, R. J., Ed.; John Wiley and Sons: London 1976; pp 1-111.
37. St. Pierre, L. E. Polymers from 1,2 epoxides: I. Chemistry. In Polyethers; Gaylord, N. G., Ed.; Interscience Publishers: New York, 1963; pp 83-168.
38. Kastens, A. S. Polymers from 1,2 epoxides: II. Applications and technologies. In Polyethers; Gaylord, N. G., Ed.; Interscience Publishers: New York, 1963; pp 169-278.
39. Moore, M. W., Carbone, F. R.; Bevan, M. J. Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell 1988, 54, 777-785.
40. Bevan, M. J. Antigen presentation to cytotoxic T lymphocytes in vivo. J. Exp. Med. 1995, 182, 639-641.
41. Newman, M. J.; Todd, C. W.; Lee, E. M.; Balusubramanian, M.; Didier, P. J.; Katz, J. M. Increasing the immunogenicity of a trivalent influenza virus vaccine with adjuvant-active nonionic block copolymers for potential use in the elderly. Mech. Aging Dev. 1997, 93, 189-203.
42. Todd, C. W.; Pozzi, L. A. M.; Guarnaccia, J. R; Balasubramanian, M.; Henk, W. G.; Younger, L. E.; Newman, M. J. Development of an adjuvant active nonionic block copolymer for use in oil-free subunit vaccines formulations. Vaccine 1997, 15, 564-570.
43. Kensil, C. R.; Wu, J. Y.; Soltysik, S. Structural and immunological characterization of the vaccine adjuvant QS-21. In Vaccine Design: The Subunit and Adjuvant Approach; Powell, M. F., Newman, M. J., Eds.; Plenum Press: New York, 1996; pp 525-542.
44. Newman, M. J.; Wu, J.-Y.; Gardner, B. H.; Munroe, K. J.; Leombruno, D.; Recchia, J.; Kensil, C. R.; Coughlin, R. T. Saponin adjuvant induction of ovalbumin-specific CD8+ cytotoxic T lymphocyte responses. J. Immunol. 1992, 148, 2357-2362.
45. Moghiini, S. M.; Hedeman, H.; Christy, N. M.; Ilium, L.; Davis, S. S. Enhanced hepatic clearance of intravenously administered sterically stabilized microspheres in zymosanstimulated rats. J. Leuk. Biol. 1993, 54, 513-517.
46. Moghimi, S. M.; Murray, J. C. Poloxamer-188 revisited: A potentially valuable immune modulator? J. Nat. Cancer Inst. 1996, 88, 766-768.
47. Moore, M. W.; Carbone, F. R.; Bevan, M. J. Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell 1988, 54, 777-785, 1988.
48. Wu, J.-Y.; Gardner, B. H.; Murphy, C. I.; Seals, J. R.; Kensil, C. R.; Recchia, J.; Beltz, G. A.; Newman, G. W.; Newman, M. J. Saponin adjuvant enhancement of antigen-specific immune responses to an experimental HPV-1 vaccine. J. Immunol. 1992, 148, 1519-1525.
49. Takahashi, H.; Takeshita, T.; Morein, B.; Putney, S.; Germain, R. N.; Berzofsky, J. A. Induction of CD8+ cytotoxic T cells by immunization with purified HPV-1 envelope protein in ISCOMs. Nature 1990, 344, 873-875.
50. Rönnberg, B.; Fekadu, M.; Morein, B. Adjuvant activity of nontoxic Quillaja saponaria Molina components for use in ISCOM matrix. Vaccine 1995, 13, 1375-1382.
51. Tarpey, L; Stacey, S. N.; Mclndoe, A.; Davies, D. H. Priming in vivo and quantification in vitro of class I MHC-restricted cytotoxic T cells to human papilloma virus type 11 early proteins (E6 and E7) using immunostimulating complexes (ISCOMs). Vaccine 1996, 14, 230-236.
52. Harding, C. V.; Collins, D.; Unanue, E. R. Processing of liposome-encapsulated antigens targeted to specific subcellular compartments. Res. Immunol. 1992, 143, 188-191.
53. Yasutomi, Y.; Koenig, S.; Woods, R. M.; Madsen, J.; Wassef, N. M.; Alving, C. R ; Klein, H. J.; Nolan, T. E.; Boots, L. J.; Kessler, J. A.; Emini, E. A.; Conley, A. J.; Letvin, N. L. A vaccine-elicited, single viral epitope-specific cytotoxic T lymphocyte response does not protect against intravenous, cell-free simian immunodeficiency virus challenge. J. Virol. 1995, 69, 2279-2284.
54. Collins, D. S.; Findlay, K.; Harding, C. V. Processing of exogenous liposome-encapsulated antigens in vivo generates class I MHC-restricted T cell responses. J. Immunol. 1992, 148, 3336-3341.
55. Taglietti, M. Vaccine adjuvancy: A new potential area of development for GM-CSF. Adv. Exp. Med. Biol. 1995, 378, 565-569.